Developing life more humann

We’re focused on creating the cutting-edge therapies and technologies that can change life for the better.

Our Technosphere® technology can be applied to a number of therapeutic areas that are both in high demand for innovation, and in need for a different kind of treatment option for people living with these conditions. Our pipeline reflects how we, as well as our partners, are applying MannKind technology to develop and advance new products to not only help people take control of their health, but truly thrive.

Orphan Lung
Endocrine
product
(collaboration and/or details)
targeted indication(s) pre-IND / formulation phase 1 phase 2 phase 3 / pivotal marketed
Afrezza® (insulin human) Inhalation Powder - USA T1 and T2 diabetes mellitus (adults)
       
Afrezza® (insulin human) Inhalation Powder - INT’L
International Expansion: Brazil (Biomm)
T1 and T2 diabetes mellitus (adults)
       
Afrezza® (insulin human) Inhalation Powder - INT’L
International Expansion: India (Cipla)
T1 and T2 diabetes mellitus (adults)
       
Pediatric Afrezza® (insulin human) Inhalation Powder
Indication Expansion
T1 and T2 diabetes mellitus (pediatrics)
       
V-Go® (once-daily wearable insulin delivery device) management of diabetes mellitus in persons requiring insulin (adults)        
Tyvaso DPI®
(collaboration with United Therapeutics)
pulmonary arterial hypertension / pulmonary hypertension associated with interstitial lung disease
       
MNKD-101 (clofazimine) nontuberculous mycobacterial lung disease
       
MNKD-201 (nintedanib) idiopathic pulmonary fibrosis
       
MNKD-301 (dornase alfa) cystic fibrosis
       
MNKD-501 (TGF-β)
(collaboration with Thirona Bio)
idiopathic pulmonary fibrosis
       
Afrezza® (insulin human) Inhalation Powder - USA
approved
Afrezza® (insulin human) Inhalation Powder - INT’L
International Expansion: Brazil (Biomm)
approved
Afrezza® (insulin human) Inhalation Powder - INT’L
International Expansion: India (Cipla)
phase3
Pediatric Afrezza® (insulin human) Inhalation Powder
Indication Expansion
phase3
V-Go® (once-daily wearable insulin delivery device)
marketed
Tyvaso DPI®
(collaboration with United Therapeutics)
approved
MNKD-101 (clofazimine)
phase3
MNKD-201 (nintedanib)
formulation
MNKD-301 (dornase alfa)
formulation
MNKD-501 (TGF-β)
(collaboration with Thirona Bio)
formulation

Learn more about

partnering with us.

Together, we can create a world without limit for all.

partner with us

Explore our published research.

See how our technologies and therapies can help more people take control of their health.

view publications